AK-1780 is under clinical development by Eli Lilly and Co and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AK-1780’s likelihood of approval (LoA) and phase transition for Neuropathic Pain (Neuralgia) took place on 28 Jul 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AK-1780 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AKP-23494954 (RQ-00466479) is under development for the treatment of neuropathic pain. The drug candidate act by targeting P2X Purinoceptor 7 (P2X7) a type of ion channel. It is administered through oral route.
Eli Lilly and Co overview
Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
Quick View AK-1780 LOA Data
|Highest Development Stage|